HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat breast cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called alisertib combined with hormone therapy for people with a common type of advanced breast cancer (HR+, HER2-). It is for those whose cancer has worsened after at least two prior hormone treatments. The goal is to find the best dose and see if the…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated May 26, 2026 03:28 UTC
-
New hope for Hard-to-Treat cancers: first human trial of BG-68501 begins
Disease control Recruiting nowThis early-phase study tests a new drug, BG-68501, in people with advanced solid tumors (like breast, ovarian, lung, or stomach cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors when used alone or with other…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated May 26, 2026 03:26 UTC
-
New pill shows promise for Hard-to-Treat breast cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer or other solid tumors that have spread. The study aims to find the safest an…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 26, 2026 03:23 UTC
-
New hope for advanced breast cancer: EP0062 trial begins
Disease control Recruiting nowThis study tests a new drug called EP0062 in people with advanced breast cancer that has come back after treatment. The goal is to find the best dose and see if it is safe and works, either alone or with other standard treatments. About 95 adults with a specific type of breast ca…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New Triple-Drug attack on Hard-to-Treat breast cancer shows promise
Disease control Recruiting nowThis study tests a new three-drug combination (VS-6766, abemaciclib, and fulvestrant) in people with a common type of advanced breast cancer (HR+/HER2-). The goal is to find the safest dose and see if the drugs can shrink tumors or stop them from growing. About 63 participants wi…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New combo therapy aims to outsmart BRCA breast cancer
Disease control Recruiting nowThis study is for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a BRCA1 or BRCA2 gene mutation. It tests whether adding a new oral drug called elacestrant to the standard treatment olaparib can help keep the cancer from growing longer …
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
Could your period change your breast cancer treatment? new study investigates
Knowledge-focused Recruiting nowThis study looks at whether the phase of a woman's menstrual cycle affects a key cancer growth marker called Ki67 in early-stage hormone-positive breast cancer. Researchers will also see if adding a genetic test (PAM50) helps doctors choose the best follow-up treatment. About 504…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated May 22, 2026 14:02 UTC